Pyrazole MAGL inhibitors

1. A compound of Formula (I):

wherein:

R 1 is —C(O)OR 15 or —C(O)NR 10 R 11 ;

R 2 is H, halogen, C 1-6 alkyl, or C 1-6 haloalkyl;

R 3 is

A is N or C(H);

X is —O—, —N(R 16 )—, or —CH 2 N(R 16 )CH 2 —;

Y is —CH 2 — or —C(O)—;

Z is —S—, —O—, or —N(R 18 )—;

R 4 is H, halogen, —OR 7 , C 1-6 alkyl, C 2-6 alkenyl, C 2-6 alkynyl, C 1-6 haloalkyl, —C(O)NR 8 R 9 , C 3-8 cycloalkyl, C 2-9 heterocycloalkyl, —C 1-6 alkyl-C 2-9 heterocycloalkyl, C 6-10 aryl, or C 1-9 heteroaryl, wherein C 3-8 cycloalkyl, C 2-9 heterocycloalkyl, —C 1-6 alkyl-C 2-9 heterocycloalkyl, C 6-10 aryl, or C 1-9 heteroaryl are optionally substituted with 1 or 2 R 14 ;

R 5 is H, halogen, C 1-6 alkyl, C 1-6 haloalkyl, C 1-6 haloalkoxy, or phenyl;

R 6 is H, halogen or C 1-6 alkyl;

R 7 is H, C 1-6 alkyl, C 1-6 haloalkyl, —C 1-6 alkyl-OH, C 2-9 heterocycloalkyl, C 6-10 aryl, or C 1-9 heteroaryl, wherein C 2-9 heterocycloalkyl, C 6-10 aryl, or C 1-9 heteroaryl are optionally substituted with 1 or 2 R 14 ;

each R 8 and each R 9 are independently selected from H and C 1-6 alkyl; or R 8 and R 9 together with the nitrogen to which they are attached are combined to form a heterocycloalkyl ring;

R 10 and R 11 are each independently H or C 1-6 alkyl;

R 12 is H, halogen, or C 1-6 alkyl;

R 13 is H or C 1-6 alkyl;

each R 14 is independently selected from halogen, —OH, C 1-6 alkyl, C 1-6 haloalkyl, C 1-6 alkoxy, —C 1-6 alkyl-OH, C 3-8 cycloalkyl, —C(O)OH, —C(O)NR 8 R 9 , —SO 2 —C 1-6 alkyl, and —N(R 17 )C(O)—C 1-6 alkyl;

R 15 is H or C 1-6 alkyl;

R 16 is H, C 1-6 alkyl, —C(O)—C 1-6 alkyl, —C 1-6 alkyl-OH, or —CH 2 CO 2 H;

R 17 is H or C 1-6 alkyl;

R 18 is H or C 1-6 alkyl;

v is 0 or 1;

n is 0 or 1;

m is 0 or 1;

p is 0, 1, or 2; and

q is 0, 1 or 2;

or a solvate, hydrate, tautomer, N-oxide, stereoisomer, or pharmaceutically acceptable salt thereof.

2. The compound of claim 1 , or a solvate, hydrate, tautomer, N-oxide, stereoisomer, or pharmaceutically acceptable salt thereof, wherein R 3 is

3. The compound of claim 2 , or a solvate, hydrate, tautomer, N-oxide, stereoisomer, or pharmaceutically acceptable salt thereof, wherein m is 1, n is 1, q is 0, and p is 2.

4. The compound of claim 3 , or a solvate, hydrate, tautomer, N-oxide, stereoisomer, or pharmaceutically acceptable salt thereof, wherein Y is —CH 2 —.

5. The compound of claim 4 , or a solvate, hydrate, tautomer, N-oxide, stereoisomer, or pharmaceutically acceptable salt thereof, wherein R 12 is H and R 13 is H.

6. The compound of claim 5 , or a solvate, hydrate, tautomer, N-oxide, stereoisomer, or pharmaceutically acceptable salt thereof, wherein A is C(H).

7. The compound of claim 6 , or a solvate, hydrate, tautomer, N-oxide, stereoisomer, or pharmaceutically acceptable salt thereof, wherein R 4 is halogen, —OR 7 , C 1-6 haloalkyl, C 2-9 heterocycloalkyl, C 6-10 aryl, or C 1-9 heteroaryl, wherein C 2-9 heterocycloalkyl, C 6-10 aryl, or C 1-9 heteroaryl are optionally substituted with 1 or 2 R 14 .

8. The compound of claim 7 , or a solvate, hydrate, tautomer, N-oxide, stereoisomer, or pharmaceutically acceptable salt thereof, wherein R 4 is halogen or C 2-9 heterocycloalkyl optionally substituted with 1 or 2 R 14 .

9. The compound of claim 8 , or a solvate, hydrate, tautomer, N-oxide, stereoisomer, or pharmaceutically acceptable salt thereof, wherein R 4 is an unsubstituted C 2-9 heterocycloalkyl.

10. The compound of claim 8 , or a solvate, hydrate, tautomer, N-oxide, stereoisomer, or pharmaceutically acceptable salt thereof, wherein R 6 is H and R 5 is H, halogen, C 1-6 alkyl, C 1-6 haloalkyl, or C 1-6 haloalkoxy.

11. The compound of claim 10 , or a solvate, hydrate, tautomer, N-oxide, stereoisomer, or pharmaceutically acceptable salt thereof, wherein R 2 is H.

12. The compound of claim 11 , or a solvate, hydrate, tautomer, N-oxide, stereoisomer, or pharmaceutically acceptable salt thereof, wherein R 1 is —C(O)OR 15 and R 15 is H.

13. The compound of claim 1 , or a solvate, hydrate, tautomer, N-oxide, stereoisomer, or pharmaceutically acceptable salt thereof, wherein the compound is

or a solvate, hydrate, tautomer, N-oxide, stereoisomer, or pharmaceutically acceptable salt thereof.

14. The compound of claim 1 , or a solvate, hydrate, tautomer, N-oxide, stereoisomer, or pharmaceutically acceptable salt thereof, wherein the compound is

or a solvate, hydrate, tautomer, N-oxide, stereoisomer, or pharmaceutically acceptable salt thereof.

15. The compound of claim 1 , or a solvate, hydrate, tautomer, N-oxide, stereoisomer, or pharmaceutically acceptable salt thereof, wherein the compound is

or a solvate, hydrate, tautomer, N-oxide, stereoisomer, or pharmaceutically acceptable salt thereof.

16. The compound of claim 1 , or a solvate, hydrate, tautomer, N-oxide, stereoisomer, or pharmaceutically acceptable salt thereof, wherein the compound is

or a solvate, hydrate, tautomer, N-oxide, stereoisomer, or pharmaceutically acceptable salt thereof.

17. The compound of claim 1 , or a solvate, hydrate, tautomer, N-oxide, stereoisomer, or pharmaceutically acceptable salt thereof, wherein the compound is

or a solvate, hydrate, tautomer, N-oxide, stereoisomer, or pharmaceutically acceptable salt thereof.

18. A compound selected from:

or a solvate, hydrate, tautomer, N-oxide, stereoisomer, or pharmaceutically acceptable salt thereof.

19. A pharmaceutical composition comprising a compound of claim 1 , or a solvate, hydrate, tautomer, N-oxide, or a pharmaceutically acceptable salt thereof, and at least one pharmaceutically acceptable excipient.

20. A method of treating chronic pain, inflammatory pain, migraine, scleroderma, or nonalcoholic fatty liver disease (NASH), in a patient in need thereof, comprising administering to the patient a therapeutically effective amount of a compound of claim 1 , or a solvate, hydrate, tautomer, N-oxide, or a pharmaceutically acceptable salt thereof.